SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Polypyrrole (PPy) is an organic polymer obtained by oxidative polymerization of pyrrole. It is a solid with the formula H(C4H2NH)nH. It is an intrinsically conducting polymer, used in electronics, optical, biological and medical fields.
In archaeology, the term in situ has been used variably to describe artifacts or features found undisturbed since deposition; however, its definition remains contested. Scholars distinguish between a broad usage, referring to materials recovered through controlled excavation, and a stricter usage applied only to those discovered in undisturbed depositional settings. Between these poles lies a continuum of depositional scenarios, from sealed habitation floors to slope or fluvial deposits, meaning that whether an object is in situ depends on site-specific formation processes and the degree to which stratigraphic—as well as spatial—relationships can be reconstructed. Recording the exact spatial coordinates, stratigraphic position, and surrounding matrix of depositional materials is necessary for understanding past human activities and historical processes. While artifacts are often removed for analysis, certain archaeological features—such as hearths, postholes, and architectural foundations—have to be thoroughly documented in place to preserve their contextual information during excavation. This documentation relies on various methods, including detailed field notes, scaled technical drawings, cartographic representation, and high-resolution photographic records. Current archaeological practice incorporates advanced digital technologies, including 3D laser scanning, photogrammetry, unmanned aerial vehicles, and Geographic Information Systems (GIS), to capture complex spatial relationships.
=== Marijuana === Similar to alcohol, marijuana is absorbed into the bloodstream and crosses the blood brain barrier. Notably, the THC released from marijuana binds to the CB-1 cannabinoid receptors, inducing various effects. These effects encompass mood changes, altered perception of time, and heightened sensitivity, among others.
Yusuf Shihab and Bashir Shihab II were the only Maronite rulers of the Emirate of Mount Lebanon. The Shihab family allied with Muhammad Ali of Egypt during his occupation of Syria, but was deposed in 1840 when the Egyptians were driven out by an Ottoman-European alliance, leading soon after to the dissolution of the Shihab emirate. Despite losing territorial control, the family remains influential in modern Lebanon, with some members having reached high political office. The Khazens opposed the creation of the "Double Qaimaqmate" in Mount Lebanon in the 1840s, which divided Mount Lebanon into Druze and Christian-run sectors, and were incensed at the appointment of a sheikh from the mixed Druze-Christian Abu'l-Lama family as the qaimaqam (deputy governor) of the Maronite section of the Qaimaqamate. The Khazens feared that such an appointment would formally subordinate them to the Abu'l-Lama sheikhs. Several Khazen family members became destitute in the 1830s and 1840s and Khazen influence over the Maronite Church waned. To compensate for their economic, social and political stagnation, the Khazens increased their pressure on the peasants of Kisrawan in the late 1850s, while also spending extravagantly. The "Druze-Christian alliance" during this century was the major factor enabling the Shehab dynasty to maintain power.
Sources: en.wikipedia.org
Deuterium (hydrogen-2, symbol 2H or D, also known as heavy hydrogen) is one of two stable isotopes of hydrogen; the other is protium, or hydrogen-1, 1H. The deuterium nucleus (deuteron) contains one proton and one neutron, whereas the far more common 1H has no neutrons. The name deuterium comes from Greek deuteros, meaning "second". American chemist Harold Urey discovered deuterium in 1931. Urey and others produced samples of heavy water in which the 2H had been highly concentrated. The discovery of deuterium won Urey a Nobel Prize in 1934. Nearly all deuterium found in nature was synthesized in the Big Bang 13.8 billion years ago, forming the primordial ratio of 2H to 1H (~26 deuterium nuclei per 106 hydrogen nuclei). Deuterium is subsequently produced by the slow stellar proton–proton chain, but rapidly destroyed by exothermic fusion reactions. The deuterium–deuterium reaction has the second-lowest energy threshold, and is the most astrophysically accessible, occurring in both stars and brown dwarfs. The gas giant planets display the primordial ratio of deuterium. Comets show an elevated ratio similar to Earth's oceans (156 deuterium nuclei per 106 hydrogen nuclei). This reinforces theories that much of Earth's ocean water is of cometary origin. The deuterium ratio of comet 67P/Churyumov–Gerasimenko, as measured by the Rosetta space probe, is about three times that of Earth water. This figure is the highest yet measured in a comet, thus deuterium ratios continue to be an active topic of research in both astronomy and climatology.
== See also == Cold chain Contamination control Counterfeit medications European Medicines Agency (EMA) Good manufacturing practice GxP Packaging and labeling Prescription Drug Marketing Act (PDMA) of the USA Package testing Site Master File Validation (drug manufacture)
==== W ==== Winter salami – a type of Hungarian salami based on a centuries-old producing tradition. Made from mangalitsa pork and spices: white pepper, allspice and others. Winter salami is cured in cold air and smoked slowly.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.